BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 35 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,587,173 | -72.1% | 9,000,000 | -71.2% | 1.54% | -32.3% |
| Q1 2023 | $20,000,750 | +30.0% | 31,250,000 | -20.9% | 2.27% | -50.6% |
| Q4 2022 | $15,386,396 | -13.5% | 39,500,000 | 0.0% | 4.59% | +136.0% |
| Q3 2022 | $17,779,000 | +11.2% | 39,500,000 | 0.0% | 1.94% | -22.9% |
| Q2 2022 | $15,990,000 | -17.4% | 39,500,000 | 0.0% | 2.52% | -30.5% |
| Q1 2022 | $19,370,000 | – | 39,500,000 | – | 3.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INHERENT GROUP, LP | 39,500,000 | $15,386,396 | 4.59% |
| Athyrium Capital Management, LP | 20,000,000 | $7,753,900 | 3.26% |
| Diameter Capital Partners LP | 43,287,000 | $16,786,915 | 2.61% |
| Affinity Asset Advisors, LLC | 10,000,000 | $3,895,290 | 1.53% |
| DeepCurrents Investment Group LLC | 39,355,000 | $14,590,746 | 0.57% |
| BRAIDWELL LP | 42,294,000 | $16,151,021 | 0.54% |
| Context Capital Management, LLC | 16,458 | $6,285 | 0.46% |
| Aequim Alternative Investments LP | 31,000,000 | $11,838,125 | 0.32% |
| ARISTEIA CAPITAL, L.L.C. | 40,816,000 | $15,586,610 | 0.31% |
| ABSOLUTE INVESTMENT ADVISERS, LLC | 5,000,000 | $1,875,000 | 0.28% |